Hinova Pharmaceuticals Inc. (SHA:688302)

China flag China · Delayed Price · Currency is CNY
42.60
+1.98 (4.87%)
At close: Mar 6, 2026
Market Cap4.22B +45.0%
Revenue (ttm)20.67M +5,535.7%
Net Income-136.69M
EPS-1.38
Shares Out99.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,462,695
Average Volume1,044,124
Open40.29
Previous Close40.62
Day's Range40.29 - 42.68
52-Week Range31.10 - 71.98
Beta-0.08
RSI38.10
Earnings DateApr 25, 2026

About Hinova Pharmaceuticals

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 174
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688302
Full Company Profile

Financial Performance

In 2025, Hinova Pharmaceuticals's revenue was 20.67 million, an increase of 5535.71% compared to the previous year's 366,836. Losses were -136.69 million, -31.48% less than in 2024.

Financial Statements